Ignite Creation Date:
2024-05-19 @ 5:34 PM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06412952
Status:
RECRUITING
Last Update Posted:
2024-05-14
First Post:
2024-04-26
Brief Title:
68Ga-NOTA-RM26 PETCT in Glioma Patients
Sponsor:
Peking Union Medical College Hospital
Organization:
Peking Union Medical College Hospital
Study Overview
Official Title:
68Ga-NOTA-RM26 PETCT in Glioma Patients
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of this study was to investigate the value of 68Ga-NOTA-RM26 an antagonist targeting gastrin-releasing peptide receptor GRPR PET tracer in the diagnosis of high WHO grade glioma and prediction the grade of glioma using positron-emission tomographycomputed tomography PETCT
Detailed Description:
The gastrin-releasing peptide receptor GRPR also known as bombesin receptor subtype II BB2 is a member of the G protein-coupled receptor family of bombesin receptors GRPR is over-expressed in various types of human tumors including breast cancer RM26 a GRPR antagonist with high affinity was discovered by peptide backbone modification of bombesin analoguesTo target gastrin-releasing peptide receptor in neoplastic cells of human breast cancer peptide NOTA-RM26 was synthesized with a PEG3 linker between NOTA and RM26 and then labeled with 68Ga An open-label brain PET CT study was designed to assess its clinical diagnostic value in patients with glioma
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None